At Optoceutics, we are committed to developing disease-modifying digital therapeutics (DTx) for neurodegenerative and psychological disorders such as Alzheimer’s, MCI, ADHD, and depression.
We work at the intersection of neuroscience, engineering and artificial intelligence to create preventive health solutions that are safe, non-invasive and drug-free.
❚ Investigating Gamma Brain Waves for Alzheimer’s Disease
Optoceutics is currently conducting a clinical study to investigate the potential effect of masked 40 Hz flickering light on Alzheimer’s disease patients.
DISCLAIMER: All devices used in trials are considerd investigational devices and limited to investigational use only.
Sign-up to our newsletter and receive new information about our developments, clinical trials and more.
❚ Selected Partners
❚ Latest News
TV2 Lorry has followed us for a long time in connection with our participation in the Danish Tech Challenge.